» Articles » PMID: 11723223

Activity of 2-substituted Lysophosphatidic Acid (LPA) Analogs at LPA Receptors: Discovery of a LPA1/LPA3 Receptor Antagonist

Overview
Journal Mol Pharmacol
Date 2001 Nov 28
PMID 11723223
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The physiological implications of lysophosphatidic acid occupancy of individual receptors are largely unknown because selective agonists/antagonists are unavailable currently. The molecular cloning of three high-affinity lysophosphatidic acid receptors, LPA1, LPA2, and LPA3, provides a platform for developing receptor type-selective ligands. Starting with an N-acyl ethanolamide phosphate LPA analog, we made a series of substitutions at the second carbon to generate compounds with varying spatial, stereochemical, and electronic characteristics. Analysis of this series at each recombinant LPA receptor using a guanosine 5'-O-(3-[35S]thio)triphosphate (GTP[gamma35S]) binding assay revealed sharp differences in activity. Our results suggest that these receptors have one spatially restrictive binding pocket that interacts with the 2-substituted moieties and prefers small hydrophobic groups and hydrogen bonding functionalities. The agonist activity predicted by the GTP[gamma35S] binding assay was reflected in the activity of a subset of compounds in increasing arterial pressure in anesthetized rats. One compound with a bulky hydrophobic group (VPC12249) was a dual LPA1/LPA3 competitive antagonist. Several compounds that had smaller side chains were found to be LPA1-selective agonists.

Citing Articles

Synthesis and Biological Evaluation of Lysophosphatidic Acid Analogues Using Conformational Restriction and Bioisosteric Replacement Strategies.

Abdelwahid M, Ohsawa K, Uwamizu A, Kano K, Aoki J, Doi T ACS Omega. 2024; 8(51):49278-49288.

PMID: 38162765 PMC: 10753746. DOI: 10.1021/acsomega.3c07668.


Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?.

Balijepalli P, Sitton C, Meier K Cells. 2021; 10(8).

PMID: 34440828 PMC: 8394178. DOI: 10.3390/cells10082059.


A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration.

Gonzalez-Gil I, Zian D, Vazquez-Villa H, Hernandez-Torres G, Martinez R, Khiar-Fernandez N J Med Chem. 2019; 63(5):2372-2390.

PMID: 31790581 PMC: 7344333. DOI: 10.1021/acs.jmedchem.9b01287.


Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.

Tigyi G, Yue J, Norman D, Szabo E, Balogh A, Balazs L Adv Biol Regul. 2018; 71:183-193.

PMID: 30243984 PMC: 6433480. DOI: 10.1016/j.jbior.2018.09.008.


LPA receptor-mediated thromboxane A release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

Dancs P, Ruisanchez E, Balogh A, Panta C, Miklos Z, Nusing R FASEB J. 2017; 31(4):1547-1555.

PMID: 28069828 PMC: 5349804. DOI: 10.1096/fj.201600735R.